Comparison of Disease Severity Classifications of Chronic Obstructive Pulmonary Disease: GOLD vs. STAR in Clinical Practice

被引:1
|
作者
Nishimura, Koichi [1 ,2 ]
Kusunose, Masaaki [3 ]
Shibayama, Ayumi [4 ]
Nakayasu, Kazuhito [5 ]
机构
[1] Natl Ctr Geriatr & Gerontol, 7-430 Morioka Cho, Obu 4748511, Japan
[2] Clin Nishimura, 4-3 Kohigashi, Kuri Cho, Ayabe 6230222, Japan
[3] Natl Ctr Geriatr & Gerontol, Dept Resp Med, 7-430 Morioka Cho, Obu 4748511, Japan
[4] Natl Ctr Geriatr & Gerontol, Dept Nursing, 7-430 Morioka Cho, Obu 4748511, Japan
[5] Kondo PP Inc, Data Res Sect, 17-25 Shimizudani Cho, Tennoujiku, Osaka 5430011, Japan
关键词
chronic obstructive pulmonary disease (COPD); disease severity; Global Initiative for Chronic Obstructive Lung Disease (GOLD); STaging of Airflow obstruction by Ratio (STAR); St. George's Respiratory Questionnaire (SGRQ); COPD Assessment Test (CAT); AIR-FLOW LIMITATION; COPD; MORTALITY; EXACERBATIONS; PREDICTORS; DYSPNEA; INDEX; RATIO; FEV1; FVC;
D O I
10.3390/diagnostics14060646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In chronic obstructive pulmonary disease (COPD), there are two known classifications for assessing what is called disease severity. One is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, which is based on the post-bronchodilator value of FEV1 (% reference). The other is the STaging of Airflow obstruction by Ratio (STAR), with four grades of severity in subjects with an FEV1/FVC ratio <0.70: STAR 1 >= 0.60 to <0.70, STAR 2 >= 0.50 to <0.60, STAR 3 >= 0.40 to <0.50, and STAR 4 <0.40. Purpose: The aim of this study was to compare the staging of COPD using the GOLD and STAR classifications in clinical practice. Methods: We reanalyzed data from our outpatient cohort study, which included 141 participants with COPD from 2015 to 2023. We compared mortality and COPD-specific health status between the GOLD 1 to 4 groups and the STAR 1 to 4 groups. Results: By simple calculation, GOLD and STAR severity classes coincided in 75 participants (53.2%). The weighted Bangdiwala B value with linear weights was 0.775. The participants were observed for up to 95 months, with a median of 54 months. Death was confirmed in 29 participants (20.5%). In univariate Cox proportional hazards analyses, there was a significant difference in mortality between the GOLD 1 and GOLD 3 + 4 groups, with the GOLD 1 group used as the reference [hazard ratio 4.222 (95% CI 1.298-13.733), p = 0.017]. However, there was no statistically significant predictive relationship between STAR 1 and STAR 2, or between STAR 1 and STAR 3 + 4. St. George's Respiratory Questionnaire (SGRQ) Total and COPD Assessment Test (CAT) scores were significantly different between all GOLD groups, except for the CAT score between GOLD 1 and GOLD 2. The SGRQ Total and CAT scores were significantly different between STAR 1 and STAR 3 + 4, but not between STAR 1 and STAR 2. Conclusion: From the perspective of all-cause mortality and COPD-specific health status, the GOLD classification is more discriminative than STAR.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure
    Hutchinson, A.
    Brand, C.
    Irving, L.
    Roberts, C.
    Thompson, P.
    Campbell, D.
    INTERNAL MEDICINE JOURNAL, 2010, 40 (05) : 364 - 371
  • [42] Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD)
    Quint, Jennifer K.
    Muellerova, Hana
    DiSantostefano, Rachael L.
    Forbes, Harriet
    Eaton, Susan
    Hurst, John R.
    Davis, Kourtney
    Smeeth, Liam
    BMJ OPEN, 2014, 4 (07):
  • [43] Treatment of Stable Chronic Obstructive Pulmonary Disease: the GOLD Guidelines
    Lee, Hobart
    Kim, Jeffrey
    Tagmazyan, Karine
    AMERICAN FAMILY PHYSICIAN, 2013, 88 (10) : 655 - 663
  • [44] Clinical practice guidelines or personalized medicine in chronic obstructive pulmonary disease?
    Jose Soler-Cataluna, Juan
    ARCHIVOS DE BRONCONEUMOLOGIA, 2018, 54 (05): : 247 - +
  • [45] Roflumilast In Chronic Obstructive Pulmonary Disease
    Sanford, Mark
    DRUGS, 2010, 70 (12) : 1615 - 1627
  • [46] Chronic Obstructive Pulmonary Disease in the elderly
    Incalzi, Raffaele Antonelli
    Scarlata, Simone
    Pennazza, Giorgio
    Santonico, Marco
    Pedone, Claudio
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (04) : 320 - 328
  • [47] Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease
    Franssen, Frits M. E.
    Spruit, Martijn A.
    Wouters, Emiel F. M.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2011, 6 : 493 - 501
  • [48] Implementation of the chronic obstructive pulmonary disease Assessment Test in clinical practice
    Abrams, Meghan E.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2021, 33 (11) : 1066 - 1073
  • [49] Outpatient Chronic Obstructive Pulmonary Disease Management: Going for the GOLD
    Bellinger, Christina R.
    Peters, Stephen P.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2015, 3 (04) : 471 - 478
  • [50] Diffusing Capacity and Mortality in Chronic Obstructive Pulmonary Disease
    Balasubramanian, Apama
    Putcha, Nirupama
    MacIntyre, Neil R.
    Jensen, Robert L.
    Kinney, Gregory
    Stlinger, William W.
    Hersh, Craig P.
    Bowler, Russell P.
    Casaburi, Richard
    Han, MeiLan K.
    Porszasz, Janos
    Barr, R. Graham
    Regan, Elizabeth
    Make, Barry J.
    Hansel, Nadia N.
    Wise, Robert A.
    McCormack, Meredith C.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2023, 20 (01) : 38 - 46